Other studies reported that ARAF mutations could drive lung cancer and that the RAF-targeted kinase inhibitor sorafenib improved the prognosis of advanced lung cancer patients, thus providing a new opportunity for lung cancer treatment [14]. Here, RAF1 is linked to lung carcinoma.